Semaglutide
Checked Oct 11, 2026 · 27 sources checked
Semaglutide is a lab-made, long-acting copy of GLP-1, a hormone the gut releases after eating. It lowers blood sugar and reduces appetite. Novo Nordisk makes it. In the US it is a prescription medicine, sold as a weekly injection or a daily tablet under the names Ozempic, Rybelsus and Wegovy. The FDA has approved it for type 2 diabetes and for long-term weight management. Some versions are also approved to lower the risk of heart attack and stroke in certain high-risk adults. One version is approved to slow kidney decline in people with type 2 diabetes and kidney disease. Another is approved to treat a scarring liver disease called MASH. Studies in heart failure and alcohol use disorder continue. A large Alzheimer's disease program found no benefit.
Education only, not medical advice. Talk to a clinician about your own situation.
Attention and coverage on this topic — not proof. Receipts below.
Reuters · Sep 30, 2026
The Wall Street Journal · Sep 22, 2026
Axios · Sep 21, 2026
Semaglutide is one of the most-read drug topics we track, and the interest is steady rather than spiking. English Wikipedia's Semaglutide article had 43,496, 42,046 and 38,937 views in July, August and September 2026. PubMed added 205 records in the 30 days to Oct 11 2026. That is close to its prior monthly rate of about 208 (625 in the preceding 90 days). Two independent publishers (Wikimedia, NLM) show sustained attention, but neither shows a spike, so we do not label it "getting hot".
In adults aged 45 or older with established cardiovascular disease and overweight or obesity but no diabetes, weekly semaglutide lowered the combined rate of cardiovascular death, heart attack or stroke versus placebo (6.5% vs 8.0%; hazard ratio 0.80) over a mean of about 40 months. More people stopped semaglutide because of side effects (16.6% vs 8.2%).
For adults with obesity but no established cardiovascular disease, does semaglutide prevent a first heart attack or stroke?
If CRAVE (NCT07218354) shows no benefit over placebo on its primary endpoint, we would describe the alcohol-use-disorder signal as not confirmed in a large trial. A clear benefit would move it into "What we know" for veterans with moderate-to-severe AUD.
If ESSENCE part 2 (NCT04822181; estimated primary completion 2029-04) shows no reduction in liver-related clinical events, we would limit the liver claim to tissue (histology) changes. So far the claim rests on histology only. The MASH approval is an accelerated approval: the FDA letter requires a 240-week placebo-controlled trial showing clinical benefit, which matches the design of ESSENCE part 2, so a null result could affect the MASH indication (U.S. FDA (Drugs@FDA), 2025-08-15).
A randomized primary-prevention outcome trial in obesity without cardiovascular disease. A positive or null result would answer the open question above either way.
Word on the street
Who's covering it lately. Coverage means people are talking about it; it isn't evidence, and it never changes our read.
- Reuters · Sep 30, 2026Read the coverage ↗
- The Wall Street Journal · Sep 22, 2026Read the coverage ↗
- Axios · Sep 21, 2026Read the coverage ↗
- Nature News · Sep 2, 2026Read the coverage ↗
For the pros: claims, studies and receipts27 sources · tap to open
9 reviewed claim records · 27 linked source receipts Inspect source receipts
Maturity: source checked
In adults aged 45 or older with established cardiovascular disease and overweight or obesity but no diabetes, weekly semaglutide lowered the combined rate of cardiovascular death, heart attack or stroke versus placebo (6.5% vs 8.0%; hazard ratio 0.80) over a mean of about 40 months. More people stopped semaglutide because of side effects (16.6% vs 8.2%).
Adults ≥45 y, established CVD, BMI ≥27, no diabetes · Outcome: First major adverse cardiovascular event (CV death, non-fatal MI, non-fatal stroke)Confidence applies to this claim and context.
Identity
Metabolic / obesity · active ingredient
Identity checked Oct 7, 2026. This establishes the catalog name; evidence assessment is separate.
NN9535 · development code
Checked facts
- In adults aged 45 or older with established cardiovascular disease and overweight or obesity but no diabetes, weekly semaglutide lowered the combined rate of cardiovascular death, heart attack or stroke versus placebo (6.5% vs 8.0%; hazard ratio 0.80) over a mean of about 40 months. More people stopped semaglutide because of side effects (16.6% vs 8.2%). PMID 37952131 ↗
- A daily semaglutide tablet reduced body weight by 13.6% on average over 64 weeks, versus 2.2% with placebo, in adults with obesity or overweight without diabetes. Gastrointestinal side effects were more common with the tablet (74.0% vs 42.2%). PMID 40934115 ↗
- In adults with obesity, or overweight with a weight-related condition, and no diabetes, weekly semaglutide injections plus lifestyle support reduced body weight by 14.9% on average over 68 weeks, versus 2.4% with placebo. PMID 33567185 ↗
- In people aged 50 or older with type 2 diabetes and cardiovascular or chronic kidney disease, daily oral semaglutide lowered the combined rate of cardiovascular death, heart attack or stroke versus placebo (12.0% vs 13.8%; hazard ratio 0.86, 95% CI 0.77-0.96) over a median of about 4 years. Kidney outcomes did not differ significantly. PMID 40162642 ↗
- In people with biopsy-confirmed MASH (fatty-liver inflammation) and moderate or advanced fibrosis, 72 weeks of semaglutide resolved steatohepatitis without worsening fibrosis in 62.9% of patients versus 34.3% on placebo (interim analysis; the trial continues to 240 weeks for clinical outcomes). PMID 40305708 ↗
- In people with early Alzheimer's disease (mild cognitive impairment or mild dementia, amyloid-confirmed), daily oral semaglutide did not slow clinical decline versus placebo over 104 weeks in two phase 3 trials (evoke and evoke+). PMID 41865758 ↗
- In people with heart failure with preserved ejection fraction and obesity, a year of weekly semaglutide improved heart-failure symptom and physical-limitation scores more than placebo (by 7.8 points on the KCCQ clinical summary score). PMID 37622681 ↗
- In people with type 2 diabetes and chronic kidney disease, weekly semaglutide lowered the risk of major kidney disease events by 24% versus placebo (hazard ratio 0.76) over a median of 3.4 years. The trial was stopped early for efficacy at a planned interim analysis. PMID 38785209 ↗
- In people with type 2 diabetes at high cardiovascular risk, semaglutide lowered major cardiovascular events versus placebo but was associated with more diabetic retinopathy complications (hazard ratio 1.76). PMID 27633186 ↗
Attention describes reviewed public attention, evidence shows study types, and confidence applies only to the stated claim. There is no overall score.
Claims
Would change this claim: If CRAVE (NCT07218354) shows no benefit over placebo on its primary endpoint, we would describe the alcohol-use-disorder signal as not confirmed in a large trial. A clear benefit would move it into "What we know" for veterans with moderate-to-severe AUD.
Source: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. · PMID 37952131 · N Engl J Med · Abstract, Results: 569/8803 (6.5%) vs 701/8801 (8.0%); HR 0.80 (95% CI 0.72-0.90); AE discontinuation 16.6% vs 8.2% · Verify ↗Source: Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity · NCT NCT03574597 · Novo Nordisk A/S · Abstract, Results: 569/8803 (6.5%) vs 701/8801 (8.0%); HR 0.80 (95% CI 0.72-0.90); AE discontinuation 16.6% vs 8.2% · Verify ↗Mapped studies / experiment families
One experiment counts once, even with several registrations or publications. Counts above describe the headline claim.
No reviewed experiment families mapped yet.
Studies & active trials
Only papers and registered trials an editor reviewed for this page. Being listed is not a finding; the claims above say what they show.
What still isn't settled?
For adults with obesity but no established cardiovascular disease, does semaglutide prevent a first heart attack or stroke?
SELECT enrolled only people who already had cardiovascular disease. A ClinicalTrials.gov search on 2026-10-11 found no registered randomized trial of semaglutide for primary prevention in obesity, only observational studies.
What would answer it: A randomized placebo-controlled outcome trial of semaglutide in adults with obesity and no prior cardiovascular disease that reports first major cardiovascular events. Observational studies alone would not settle it.
Already settled: in adults with established cardiovascular disease and overweight or obesity but no diabetes, semaglutide reduced major cardiovascular events versus placebo (SELECT). In early Alzheimer's disease it did not slow decline (evoke/evoke+).